Celltrion plans to lead global drug development by 2028, targeting 13 new drug applications.

South Korean biopharmaceutical firm Celltrion outlined plans to become a global leader in drug development by 2028, aiming to submit 13 Investigational New Drug applications. The company's strategy focuses on next-generation antibody drug conjugates and multispecific antibodies, with key developments including CT-P70 and CT-P71 for solid cancers and dual-payload ADCs. Celltrion also seeks to enter the contract development and manufacturing business.

2 months ago
4 Articles